Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function, Am. J. Respir. Crit. Care Med, vol.183, pp.627-634, 2011. ,
Cystic fibrosis airway epithelium remodelling: involvement of inflammation, J. Pathol, vol.235, pp.408-419, 2015. ,
Review paper Cathelicidin impact on inflammatory cells. Cent, Eur. J. Immunol, vol.2, pp.225-235, 2015. ,
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebocontrolled, phase 2b trial, Lancet Respirat. Med, vol.3, issue.15, pp.245-248, 2015. ,
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis, Thorax, 2017. ,
Clarithromycin Enhances the Antibacterial Activity and Wound Healing Capacity in Type 2 Diabetes Mellitus by Increasing LL-37 Load on, Neutrophil Extracellular Traps. Front. Immunol, vol.9, p.2064, 2018. ,
Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis, BMJ, vol.310, pp.1571-1572, 1995. ,
Strategies for measuring airway mucus and mucins, Respir. Res, vol.20, p.261, 2019. ,
Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis, Lancet, vol.2, pp.686-688, 1985. ,
Unravelling the role of sphingolipids in cystic fibrosis lung disease, Chem. Phys. Lipids, vol.200, pp.94-103, 2016. ,
Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway, Pediatr. Pulmonol, vol.54, pp.5-12, 2019. ,
Inhaled corticosteroids for cystic fibrosis, Cochrane Database Syst. Rev, vol.10, p.1915, 2014. ,
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.173, pp.1356-1362, 2006. ,
Salt-Independent Abnormality of Antimicrobial Activity in Cystic Fibrosis Airway Surface Fluid, Am. J. Respir. Cell Mol. Biol, vol.25, pp.21-25, 2001. ,
The Antibacterial and Anti-inflammatory Activity of Chicken Cathelicidin-2 combined with Exogenous Surfactant for the Treatment of Cystic Fibrosis-Associated Pathogens, Sci. Rep, vol.7, p.15545, 2017. ,
Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways, J. Pathol, vol.245, pp.410-420, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02390385
Emerging microRNA Therapeutic Approaches for Cystic Fibrosis, Front. Pharmacol, vol.9, p.1113, 2018. ,
miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis, Front. Immunol, vol.10, p.2643, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02390394
Transcription factors in airway diseases, Lab. Invest, vol.86, pp.867-872, 2006. ,
IL-8 Regulates Mucin Gene Expression at the Posttranscriptional Level in Lung Epithelial Cells, J. Immunol, vol.183, pp.2159-2166, 2009. ,
Role of the Microbiota in Immunity and Inflammation, Cell, vol.157, pp.121-141, 2014. ,
Epithelial Chloride Transport by CFTR Requires TMEM16A, Sci. Rep, vol.7, p.12397, 2017. ,
Plasma membrane-localized TMEM16 proteins are indispensable for expression of CFTR, J. Mol. Med. (Berl.), vol.97, pp.711-722, 2019. ,
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections, Respir. Med, vol.117, pp.190-197, 2016. ,
Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation, Proc. Natl. Acad. Sci, vol.113, pp.4350-4355, 2016. ,
Ajulemic acid: potential treatment for chronic inflammation, Pharmacol. Res. Perspect, vol.6, p.394, 2018. ,
A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia, Science, vol.337, pp.937-941, 2012. ,
Azithromycin and Chloramphenicol Diminish Neutrophil Extracellular Traps (NETs) Release, Int. J. Mol. Sci, vol.18, p.2666, 2017. ,
Molecular modelling and molecular dynamics of CFTR, Cell Mol. Life Sci, vol.74, pp.3-22, 2017. ,
Oxidant stress suppresses CFTR expression, Am. J. Physiol. Cell Physiol, vol.290, 2006. ,
Antioxidants in cystic fibrosis, Conclusions from the CF antioxidant workshop, vol.4, pp.15-31, 2003. ,
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy, J. Cyst. Fibros, vol.14, pp.419-430, 2015. ,
TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity, Science, vol.322, pp.590-594, 2008. ,
, , 2014.
, Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis, Biochim. Biophys. Acta, vol.1840, pp.586-594
Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis, Redox Biol, vol.32, p.101436, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02471393
Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis, Am. J. Respir. Crit. Care Med, vol.195, pp.1384-1393, 2017. ,
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study, Crit. Care Med, vol.36, pp.1089-1096, 2008. ,
Novel Therapeutic Strategies Applied to Pseudomonas aeruginosa Infections in Cystic Fibrosis, Materials, vol.12, p.4093, 2019. ,
Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin-32-induced inflammation, Immunology, vol.143, pp.68-80, 2014. ,
The effects of lipoxin A4 on airway responses in asthmatic subjects, Am. Rev. Respir. Dis, vol.145, pp.1281-1284, 1992. ,
Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia, Antimicrob. Agents Chemother, vol.60, pp.4991-5000, 2016. ,
Antioxidant supplementation for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, vol.10, p.7020, 2019. ,
Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial, Thorax, vol.61, pp.895-902, 2006. ,
Cystic fibrosis: a mucosal immunodeficiency syndrome, Nat. Med, vol.18, pp.509-519, 2012. ,
Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis, Am. J. Physiol. Lung Cell Mol. Physiol, vol.284, pp.997-1003, 2003. ,
Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice, J. Cyst. Fibros, vol.16, pp.671-680, 2017. ,
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis, Am. J. Respir. Crit. Care Med, vol.201, issue.8, pp.946-954, 2020. ,
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N. Engl. J. Med, vol.379, pp.1599-1611, 2018. ,
Exploring the effect of chirality on the therapeutic potential of Nalkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease, Eur. J. Med. Chem, vol.175, pp.63-71, 2019. ,
Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells, Mol. Ther, vol.28, issue.4, pp.1190-1199, 2020. ,
Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.152, pp.765-774, 1995. ,
Critical role of cytosolic phospholipase A2{alpha} in bronchial mucus hypersecretion in CFTR-deficient mice, Eur. Respir. J, vol.36, 2010. ,
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR, J. Cystic Fibrosis, vol.16, pp.371-379, 2017. ,
Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients, Int. J. Med. Microbiol, vol.300, pp.573-577, 2010. ,
Systematic review of N-acetylcysteine in cystic fibrosis, Acta Paediatr, vol.88, pp.38-41, 1999. ,
Cystic fibrosis: an inherited disease affecting mucin-producing organs, Int. J. Biochem. Cell Biol, vol.52, pp.136-145, 2014. ,
An Improved Inhaled Mucolytic to Treat Airway Mucoobstructive Diseases, Am. J. Respir. Crit. Care Med, vol.199, pp.171-180, 2019. ,
Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis, Clin. Transl. Sci, vol.10, pp.28-34, 2017. ,
EMPIRE-CF: A phase II randomized placebo-controlled trial of oncedaily, oral acebilustat in adult patients with cystic fibrosis -Study design and patient demographics, Contemp. Clin. Trials, vol.72, pp.86-94, 2018. ,
Cystic fibrosis, Lancet, vol.388, issue.16, pp.576-582, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02299268
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics, Pediatr. Pulmonol, vol.55, issue.1, pp.35-57, 2019. ,
Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial, Lancet, vol.360, pp.978-984, 2002. ,
OligoG CF-5/20 normalizes cystic fibrosis mucus by chelating calcium, Clin. Exp. Pharmacol. Physiol, vol.44, pp.639-647, 2017. ,
Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis, Sci. Transl. Med, vol.11, 2019. ,
Expression of miR-93 and IL-8 During Pseudomonas aeruginosa Mediated Induction of Pro-Inflammatory Responses, Am. J. Respir. Cell Mol. Biol, vol.50, issue.6, pp.1144-1155, 2014. ,
Airway mucus function and dysfunction, N. Engl. J. Med, vol.363, pp.2233-2247, 2010. ,
Can innate immunity be enhanced to treat microbial infections?, Nat. Rev. Microbiol, vol.2, pp.497-504, 2004. ,
Association of cystic fibrosis with abnormalities in fatty acid metabolism, N. Engl. J. Med, vol.350, pp.560-569, 2004. ,
Nuclear lipid mediators: Role of nuclear sphingolipids and sphingosine-1-phosphate signaling in epigenetic regulation of inflammation and gene expression, J. Cell. Biochem, vol.119, issue.8, pp.6337-6353, 2018. ,
The role of matrix metalloproteinases in cystic fibrosis lung disease, Eur. Respir. J, vol.38, pp.721-727, 2011. ,
Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis, J. Cyst. Fibros, vol.15, pp.227-233, 2016. ,
Fibrosis, Oxidative stress and antioxidant therapy in cystic fibrosis, Biochim. Biophys. Acta, vol.1822, pp.690-713, 2012. ,
A role for 12R-lipoxygenase in MUC5AC expression by respiratory epithelial cells, Eur. Respirat. J, vol.40, pp.714-723, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01004450
Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrugresistant Pseudomonas aeruginosa, BMC Microbiol, vol.19, p.54, 2019. ,
Bactericidal/permeabilityincreasing protein-lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia, Crit. Care Med, vol.29, pp.130-135, 2001. ,
Non-coding RNA in cystic fibrosis, Biochem. Soc. Trans, vol.46, issue.3, pp.619-630, 2018. ,
Implications of the innate immune response to adenovirus and adenoviral vectors, Future Virol, vol.6, pp.357-374, 2011. ,
Fenretinide corrects newly found ceramide deficiency in cystic fibrosis, Am. J. Respir. Cell Mol. Biol, vol.38, pp.47-56, 2008. ,
Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide, Am. J. Respir. Cell Mol. Biol, vol.41, pp.100-106, 2009. ,
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis, Crit. Care Med, vol.41, pp.706-716, 2013. ,
50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams, Platelets, vol.23, pp.415-422, 2012. ,
The immunology of host defence peptides: beyond antimicrobial activity, Nat. Rev. Immunol, vol.16, pp.321-334, 2016. ,
Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-kB Signaling Pathways, J. Immunol, vol.203, 2019. ,
Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure, J. Clin. Invest, vol.124, pp.3047-3060, 2014. ,
Mucolytics in cystic fibrosis, Paediatric Respirat. Rev, vol.8, pp.24-29, 2007. ,
Physiological impact of abnormal lipoxin A(4) production on cystic fibrosis airway epithelium and therapeutic potential, BioMed. Res. Int, p.781087, 2015. ,
Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis, J. Cystic Fibrosis, vol.46, issue.3, pp.619-630, 2020. ,
Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms, Exp. Dermatol, vol.22, pp.210-215, 2013. ,
Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa, Clin. Exp. Immunol, vol.124, pp.69-76, 2001. ,
URL : https://hal.archives-ouvertes.fr/inserm-00152211
Alpha-1 Antitrypsin-A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis, Int. J. Mol. Sci, vol.21, p.836, 2020. ,
Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights, Genes (Basel), vol.10, p.180, 2019. ,
Airway epithelial cell inflammatory signalling in cystic fibrosis, Int. J. Biochem. Cell Biol, vol.40, pp.1703-1715, 2008. ,
Hyperinflammation in airways of cystic fibrosis patients: what's new?, Expert Rev. Mol. Diagn, vol.8, pp.359-363, 2008. ,
Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis, Elife, vol.9, 2020. ,
Dynamic modulation of ANO1/TMEM16A HCO3(-) permeability by Ca2+/calmodulin, Proc. Natl. Acad. Sci. U.S.A, vol.110, pp.360-365, 2013. ,
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway, Nat. Immunol, vol.5, pp.388-392, 2004. ,
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N. Engl. J. Med, vol.379, pp.1612-1620, 2018. ,
Early pulmonary inflammation in infants with cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.151, pp.1075-1082, 1995. ,
Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation, Genes, vol.10, p.183, 2019. ,
The effect of calcipotriol on the expression of human beta defensin-2 and LL-37 in cultured human keratinocytes, Clin. Dev. Immunol, p.645898, 2009. ,
Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis, N. Engl. J. Med, vol.325, pp.533-538, 1991. ,
Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects, J. Pharmacol. Exp. Ther, vol.306, pp.1086-1091, 2003. ,
Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps, Antimicrobial. Agents Chemother, vol.60, pp.1040-1048, 2016. ,
Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis, Nihon Kyobu Shikkan Gakkai zasshi, vol.25, pp.632-642, 1987. ,
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, vol.384, pp.644-648, 1996. ,
AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense, Trends Immunol, vol.30, pp.131-141, 2009. ,
beta-Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells, Front. Pharmacol, vol.8, p.236, 2017. ,
Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis, Cochrane Database Syst. Rev, vol.4, p.1505, 2007. ,
Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, vol.4, p.1505, 2016. ,
Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, 2019. ,
Anti-Infectives Restore ORKAMBI((R)) Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of P. aeruginosa, Biomolecules, vol.10, p.334, 2020. ,
Successful adjunctive use of bacteriophage therapy for treatment of multidrugresistant Pseudomonas aeruginosa infection in a cystic fibrosis patient, Infection, vol.47, pp.665-668, 2019. ,
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans, Br. J. Clin. Pharmacol, vol.72, pp.282-293, 2011. ,
Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases, Biochimie, vol.122, pp.151-168, 2016. ,
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine, Front. Pharmacol, vol.10, p.1662, 2019. ,
The Ancestral N-Terminal Domain of Big Defensins Drives Bacterially Triggered Assembly into Antimicrobial Nanonets, vol.10, pp.1821-1840, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02328576
Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice, Eur. Respir. J, vol.37, pp.72-78, 2011. ,
Antimicrobial Peptides in Human Disease: Therapeutic Approaches. Second of Two Parts, Curr. Pharm. Des, vol.24, pp.1148-1156, 2018. ,
, , 1996.
, Corticostatins/defensins inhibit in vitro NK activity and cytokine production by human peripheral blood mononuclear cells, Regul. Pept, vol.62, pp.13-21
Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough', Evid. Based. Med, vol.21, pp.83-86, 2016. ,
Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis, Am. Rev. Respir. Dis, vol.148, pp.1056-1060, 1993. ,
Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis, Am. J. Respir. Crit. Care Med, vol.200, pp.1381-1391, 2019. ,
Granulysin-derived peptides demonstrate antimicrobial and antiinflammatory effects against Propionibacterium acnes, J. Invest. Dermatol, vol.125, pp.256-263, 2005. ,
Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential, Am. J. Respir. Crit. Care Med, vol.201, pp.141-147, 2020. ,
Impact of CFTR DeltaF508 mutation on prostaglandin E2 production and type IIA phospholipase A2 expression by pulmonary epithelial cells, Am. J. Physiol. Lung Cell Mol. Physiol, vol.289, pp.816-824, 2005. ,
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, New Engl. J. Med, vol.381, pp.1809-1819, 2019. ,
Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis, Cell Physiol. Biochem, vol.54, pp.110-125, 2020. ,
A Crucial Role of Flagellin in the Induction of Airway Mucus Production by Pseudomonas aeruginosa, PloS One, vol.7, 2012. ,
Deficiency of Mannose-Binding Lectin Greatly Increases Susceptibility to Postburn Infection with Pseudomonas aeruginosa, J. Immunol, vol.176, pp.1769-1775, 2006. ,
Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells, Mol. Biosyst, vol.5, pp.483-496, 2009. ,
Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic Fibrosis Strains: First Steps Towards Treatment and Prevention, PloS One, vol.6, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01425539
Characterization of the Mouse Beta Defensin 1, Defb1. Mutant Mouse Model, Infection Immun, vol.70, pp.3053-3060, 2002. ,
Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis, J. Cyst. Fibros, vol.12, pp.241-248, 2013. ,
Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis, J. Pediatr, vol.162, pp.676-680, 2013. ,
Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles, Mol. Ther, vol.20, pp.590-600, 2012. ,
Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis, Am. J. Respir. Crit. Care Med, vol.165, pp.911-915, 2002. ,
Enhanced IL-1beta-induced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NF-kappaB signaling, Biochem. Biophys. Res. Commun, vol.357, pp.402-407, 2007. ,
Modulation of Neutrophil Apoptosis by Antimicrobial Peptides, ISRN Microbiol, vol.2012, pp.1-12, 2012. ,
Inhaled mannitol for cystic fibrosis, Cochrane Database Syst. Rev, vol.2, p.8649, 2018. ,
Inflammation and its genesis in cystic fibrosis, Pediatr. Pulmonol, vol.50, pp.39-56, 2015. ,
Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis, Am. J. Respir. Crit. Care Med, vol.201, pp.430-437, 2020. ,
Amazing chloride channels: an overview, Acta Physiol. Scand, vol.177, pp.119-147, 2003. ,
Early airway infection, inflammation, and lung function in cystic fibrosis, Arch. Dis. Child, vol.87, pp.306-311, 2002. ,
The use of antiinflammatory medications in cystic fibrosis: trends and physician attitudes, Chest, vol.115, pp.1053-1058, 1999. ,
Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by Pseudomonas aeruginosa-pilot study, Ital. J. Pediatr, vol.45, p.41, 2019. ,
Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis, Cochrane Database Syst. Rev, vol.12, p.12300, 2019. ,
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies, Biotechnol. Adv, vol.37, pp.177-192, 2019. ,
The critical role of iron in hostbacterial interactions, J. Clin. Invest, vol.61, pp.1428-1440, 1978. ,
Effects of hydrogen peroxide on MAPK activation, IL-8 production and cell viability in primary cultures of human bronchial epithelial cells, J. Cell Biochem, vol.93, pp.142-152, 2004. ,
CFTR inhibition mimics the cystic fibrosis inflammatory profile, Am. J. Physiol. Lung Cell Mol. Physiol, vol.292, pp.383-395, 2007. ,
Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity, Nat. Commun, vol.5, p.5105, 2014. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02863033
Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators, Pediatr. Pulmonol, vol.54, pp.46-55, 2019. ,
Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections, Proc. Natl. Acad. Sci. U.S.A, vol.97, pp.8822-8828, 2000. ,
microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A4 receptor-dependent mechanisms of inflammation resolution and antimicrobial defense, J. Immunol, vol.7, pp.6786-6791, 2005. ,
A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte, Nature, vol.560, pp.377-381, 2018. ,
Physical and functional properties of airway secretions in cystic fibrosis-therapeutic approaches, Respiration, vol.62, 1995. ,
A dual-action peptide-containing hydrogel targets wound infection and inflammation, Sci. Transl. Med, vol.12, p.6601, 2020. ,
SLPI and AnxA2 expression in neoplasm-free palatine tonsils is associated with smoking habit of individuals, Mol. Clin. Oncol, vol.7, pp.427-434, 2017. ,
Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis, Lancet, vol.372, pp.61162-61171, 2008. ,
Oxidative stress and regulation of glutathione in lung inflammation, Eur. Respir. J, vol.16, pp.534-554, 2000. ,
Evidence of Chronic Inflammation in Morphologically Normal Small Intestine of Cystic Fibrosis Patients, Pediatr. Res, vol.47, pp.344-350, 2000. ,
, Neutrophil Extracellular Trap Formation: Physiology, Pathology, and Pharmacology. Biomolecules, vol.9, p.365, 2019.
Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis, Eur. Respir. J, vol.30, pp.286-292, 2007. ,
, CXCR2 Antagonist MK-7123. A Phase, 2015.
, Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease, Am. J. Respir. Crit. Care Med, vol.191, pp.1001-1011
Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell, Glycoconj J, vol.18, pp.649-659, 2001. ,
Cystic fibrosis airway epithelial Ca2+ i signaling: the mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia, J. Biol. Chem, vol.280, pp.10202-10209, 2005. ,
Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem, J. Antimicrobial. Chemother, vol.66, pp.2022-2027, 2011. ,
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Science, vol.245, pp.1066-1073, 1989. ,
Susceptibility to Infectious Diseases Based on Antimicrobial Peptide Production, Infection Immun, vol.77, pp.4690-4695, 2009. ,
New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis, Br. J. Pharmacol, vol.173, pp.1728-1741, 2016. ,
Inflammation in cystic fibrosis: An update, Pediatr. Pulmonol, vol.53, 2018. ,
Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs, Science, vol.321, pp.1837-1841, 2008. ,
Antibiofilm and mucolytic action of nitric oxide delivered via gas or macromolecular donor using in vitro and ex vivo models, J. Cystic Fibrosis, vol.20, pp.30075-30078, 2020. ,
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis, N. Engl. J. Med, vol.377, pp.2024-2035, 2017. ,
Anoctamin 1 dysregulation alters bronchial epithelial repair in cystic fibrosis, Biochim. Biophys. Acta, vol.1832, pp.2340-2351, 2013. ,
Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis, J. Cyst. Fibros, vol.10, pp.31-36, 2011. ,
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial, Jama, vol.303, pp.1707-1715, 2010. ,
Restoration of chloride efflux by azithromycin in airway epithelial cells of cystic fibrosis patients, Antimicrob. Agents Chemother, vol.55, pp.1792-1793, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02405807
Azithromycin fails to reduce inflammation in cystic fibrosis airway epithelial cells, Eur. J. Pharmacol, vol.674, pp.1-6, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-02398074
ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis, vol.8, p.49248, 2019. ,
Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects, Paediatr. Drugs, vol.7, pp.353-363, 2005. ,
Expression cloning of TMEM16A as a calcium-activated chloride channel subunit, Cell, vol.134, pp.1019-1029, 2008. ,
Cationic antimicrobial peptides and their multifunctional role in the immune system, Crit. Rev. Immunol, vol.20, pp.407-431, 2000. ,
Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms, FASEB J, vol.31, pp.1273-1288, 2017. ,
Airway acidification initiates host defense abnormalities in cystic fibrosis mice, Science, vol.351, pp.503-507, 2016. ,
Antioxidant micronutrients for lung disease in cystic fibrosis, Cochrane Database Syst. Rev, vol.12, p.7020, 2010. ,
Tumor necrosis factor -converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells, Proc. Natl. Acad. Sci, vol.100, pp.11618-11623, 2003. ,
Meta-analysis Reveals Potential Influence of Oxidative Stress on the Airway Microbiomes of Cystic Fibrosis Patients, Genom. Proteomics Bioinf, vol.17, pp.590-602, 2019. ,
Anti-Inflammatory Action of an Antimicrobial Model Peptide That Suppresses the TRIF-Dependent Signaling Pathway via Inhibition of Toll-Like Receptor 4 Endocytosis in Lipopolysaccharide-Stimulated Macrophages, PloS One, vol.10, 2015. ,
Ataluren for the treatment of cystic fibrosis, Expert Rev. Respir. Med, vol.10, pp.387-391, 2016. ,
TMEM16A chloride channel does not drive mucus production, Life Sci. Alliance, vol.2, p.201900462, 2019. ,
Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis, Sci. Rep, vol.9, p.6516, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02125198
Relationship Between Fat-Soluble Vitamin Supplementation and Blood Concentrations in Adolescent and Adult Patients With Cystic Fibrosis, Nutr. Clin. Pract, vol.29, pp.491-497, 2014. ,
Anti-inflammatory Properties of Antimicrobial Peptides and Peptidomimetics: LPS and LTA Neutralization, Methods Mol. Biol, vol.1548, pp.369-386, 2017. ,
Human b-defensin-3 increases the expression of interleukin-37 through CCR6 in human keratinocytes, J. Dermatol. Sci, vol.77, pp.46-53, 2015. ,
Interleukin-1b and Tumor Necrosis Factor-a InduceMUC5ACOverexpression through a Mechanism Involving ERK/p38 Mitogen-activated Protein Kinases-MSK1-CREB Activation in Human Airway Epithelial Cells, J. Biol. Chem, vol.278, pp.23243-23250, 2003. ,
Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis, Am. J. Physiol. Cell Physiol, vol.290, pp.741-749, 2006. ,
MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology, Nat. Commun, vol.8, p.710, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01614066
Mutations of Cystic Fibrosis Transmembrane Conductance Regulator Gene Cause a Monocyte-Selective Adhesion Deficiency, Am. J. Respiratory Crit. Care Med, vol.193, pp.1123-1133, 2016. ,
Azithromycin for cystic fibrosis, Eur. Respiratory J, vol.24, pp.834-838, 2004. ,
Macrolide antibiotics for cystic fibrosis, Cochrane Database Syst. Rev, vol.11, 2012. ,
Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth, Sci. Trans. Med, vol.2, pp.29-31, 2010. ,
Origins of cystic fibrosis lung disease, New Engl. J. Med, vol.372, pp.351-362, 2015. ,
Fatty acid metabolism in cystic fibrosis, Prostaglandins Leukot. Essent. Fatty Acids, vol.83, pp.121-129, 2010. ,
Bacteriophage Therapy, Annu. Rev. Microbiol, vol.55, pp.437-451, 2001. ,
Inhibitory Effects of Antimicrobial Peptides on Lipopolysaccharide-Induced Inflammation, Mediators Inflammation, pp.1-8, 2015. ,
Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis, J. Clin. Invest, vol.120, pp.3149-3160, 2010. ,
Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro, Am. J. Pathol, vol.153, issue.10, pp.65633-65640, 1998. ,
Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells, Am. J. Pathol, vol.155, issue.10, pp.65143-65150, 1999. ,
Interleukin-10 Inhibits Elevated Chemokine Interleukin-8 and Regulated on Activation Normal T Cell Expressed and Secreted Production in Cystic Fibrosis Bronchial Epithelial Cells by Targeting the I(k)B Kinase alpha/beta Complex, Am. J. Pathol, vol.162, issue.10, pp.63820-63825, 2003. ,
URL : https://hal.archives-ouvertes.fr/inserm-00148987
Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells, Cell Signal, vol.18, pp.652-660, 2006. ,
Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions, Am. J. Physiol. Lung Cell Mol. Physiol, vol.290, pp.588-596, 2006. ,
Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8, Am. J. Physiol. Lung Cell Mol. Physiol, vol.278, pp.33-41, 2000. ,
The CF salt controversy: in vivo observations and therapeutic approaches, Mol. Cell, vol.8, pp.149-158, 2001. ,
Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis, Respirology, vol.22, pp.1084-1092, 2017. ,
Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease, J. Cyst. Fibros, vol.14, pp.228-236, 2015. ,
Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis, Nat. Med, vol.14, pp.382-391, 2008. ,
Inflammation and infection in naive human cystic fibrosis airway grafts, Am. J. Respir. Cell Mol. Biol, vol.23, pp.121-127, 2000. ,
Primary inflammation in human cystic fibrosis small airways, Am. J. Physiol. Lung Cell Mol. Physiol, vol.283, pp.445-451, 2002. ,
High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis, Proc. Natl. Acad. Sci. U.S.A, vol.103, pp.4628-4633, 2006. ,
Characterization of gallium resistance induced in a Pseudomonas aeruginosa cystic fibrosis isolate, Arch. Microbiol, vol.202, pp.617-622, 2020. ,
In Vitro Activity of Doripenem against Pseudomonas aeruginosa and Burkholderia cepacia Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis Patients, Antimicrobial. Agents Chemother, vol.50, pp.819-821, 2006. ,
Characterization of Defects in Ion Transport and Tissue Development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Knockout Rats, PloS One, vol.9, 2014. ,
Type IIA Secreted Phospholipase A2 in Host Defense against Bacterial Infections, Trends Immunol, vol.41, pp.313-326, 2020. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02863073
Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review, Adv. Ther, vol.37, pp.61-82, 2020. ,
Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia, Mol. Biol. Cell, vol.23, pp.4188-4202, 2012. ,
Nebulised lipid-polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells, ERJ Open Res, vol.5, pp.161-2018, 2019. ,
Host mucin glycosylation plays a role in bacterial adhesion in lungs of individuals with cystic fibrosis, Expert Rev. Respir. Med, vol.7, pp.553-576, 2013. ,
Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide, Int. Immunopharmacol, vol.6, pp.1651-1664, 2006. ,
Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial, Crit. Care Med, vol.43, pp.1832-1838, 2015. ,
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR, N. Engl. J. Med, vol.373, issue.3, pp.220-231, 2015. ,
Antimicrobial peptides: Promising alternatives in the post feeding antibiotic era, Med. Res. Rev, vol.39, pp.831-859, 2019. ,
Nebulised hypertonic saline for cystic fibrosis, Cochrane Database Syst. Rev, vol.9, p.1506, 2018. ,
Cystic fibrosis microbiology: Advances in antimicrobial therapy, J. Cyst. Fibros, vol.14, pp.551-560, 2015. ,
Chronic Antibiotic Use in Cystic Fibrosis: A Fine Balance, Ann. Am. Thoracic Soc, vol.15, pp.667-668, 2018. ,
Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial, Pulm. Pharmacol. Ther, vol.56, pp.86-93, 2019. ,
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort, Eur. Respirat. J, vol.55, 2020. ,
Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema, Br. J. Dermatol, vol.168, pp.172-178, 2013. ,
Dornase alfa for cystic fibrosis, Cochrane Database Syst. Rev, vol.9, p.1127, 2018. ,
TMEM16A confers receptor-activated calcium-dependent chloride conductance, Nature, vol.455, pp.1210-1215, 2008. ,
12-lipoxygenase: a potential target for novel anti-platelet therapeutics, Cardiovasc. Hematol. Agents Med. Chem, vol.9, pp.154-164, 2011. ,
Anti-inflammatory capabilities of macrolides, Pharmacol. Res, vol.44, pp.451-454, 2001. ,
Antimicrobial peptides of multicellular organisms, Nature, vol.415, pp.389-395, 2002. ,
Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice, Am. J. Respir. Crit. Care Med, vol.178, pp.1245-1256, 2008. ,